Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B.

Shun IshidoNobuharu TamakiNaoki UchiharaKeito SuzukiYuki TanakaHaruka MiyamotoMichiko YamadaHiroaki MatsumotoTsubasa NobusawaTaisei KeitokuKenta TakauraShohei TanakaChiaki MaeyashikiYutaka YasuiYuka TakahashiKaoru TsuchiyaHiroyuki NakanishiJun ItakuraMasayuki KurosakiNamiki Izumi

Published in: JGH open : an open access journal of gastroenterology and hepatology (2023)

Switching from ETV to TAF increases the CVR rate in patients with LLV or occasional detectable HBV DNA and could be an alternative treatment option.

Keyphrases

hepatitis b virus
antiretroviral therapy
acute lymphoblastic leukemia
circulating tumor
hiv infected
single molecule
hiv infected patients
combination therapy
circulating tumor cells